Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting
Phase: PHASE2
Conditions: Non Small Cell Lung Cancer
Sponsor: Spanish Lung Cancer Group

 
                                                                                          PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 Official Title: 
 
 
 
NCT Number: 
 
 
 
Document Dates: Summary of Protocol Amendment Version 2.1:  
28 December 2018 
 

 
                               2       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               3       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
Contacts 
 
Trial Chair (Principal 
Investigator) 
Dr. Remei Blanco, Ph D  
Oncology Service 
Consorci Sanitari de Terrassa 
Ctra. Torrebonica, s.n. 
08227 Terrassa, Barcelona 
Seguridad y Regulación 
(Safety and Regulatory 
Affairs) 
Avenida Meridiana 358, 6ªplanta 
08027 Barcelona 
Tel. 93 430 20 06 
Fax. 93 419 17 68 
Email: 
pharmacovigilance.slcg@gecp.org 
Monitor/CRA 
 
 
 
Project Manager 
Kenia López 
Avenida Meridiana 358, 6ªplanta 
08027 Barcelona 
Tel. 93 430 20 06 
Fax. 93 419 17 68 
Eva Pereira 
Avenida Meridiana 358, 6ªplanta 
08027 Barcelona 
Tel. 93 430 20 06 
Fax. 93 419 17 68 
 

 
                               4       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
 
Signature 
 
 
 
Dr. Mariano Provencio 
Fundación GECP President 

 
                               5       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
 

 
                               6       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
INDEX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
                               7       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
                               8       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
                               9       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
                               10       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
                               11       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
 
 
 

 
                               12       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               13       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
 
 
Main inclusion criteria: 
-Treatment-naive stage IV NSCLC 
-Squamous and non-Squamous 
Basal screening 
CGA 
MK-3475 
200 mg Q3W 
PD 
SFU 
CGA = Comprehensive Geriatric Assessment        PD = Progressive Disease   
SFU = Survival Follow-up   

 
                               14       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               15       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
Fundación GECPAvenida Meridiana 358, 6ªplanta 
08027 Barcelona 
 
Monitor 
Kenia López 
Fundación GECPAvenida Meridiana 358, 6ªplanta  
08027 Barcelona 
e-mail: klopez@gecp.org 
 

 
                               16       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               17       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               18       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               19       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               20       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               21       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               22       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               23       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               24       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               25       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               26       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               27       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               28       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               29       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               30       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               31       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               32       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               33       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               34       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               35       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               36       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               37       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
                               38       
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                                                                         39                              
 
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 
Disease details 
 
 

 
 
 
 
 
                                                                         40                              
 
PEBEL_GECP 16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               41 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               42 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               43 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               44 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               45 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               46 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               47 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               48 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               49 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               50 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               51 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               52 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               53 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               54 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               55 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               56 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               57 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               58 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               59 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               60 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               61 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               62 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               63 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 

 
 
 
 
 
                               64 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
                               65 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 
 
1
2
J ClinOncol 2008 
26: 4617–25. 
 
3 R. Blanco, I. Maestu, M. G. de la Torre et al. 
4
5
6
7
8
9Garon EB, Rizvi NA, Hui R, et al. 
 

 
 
 
 
 
                               66 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 
 
11
Lancet 2016; 387: 1540–50 
 
12 Reck M, Delvys Rodríguez-Abreu D,  Robinson AG, et al.  
15 Repetto L, Fratino L, Audisio RA, et al. 
16
17
18
J Natl Cancer Inst 2012;104:1133–1163. 
 
 Gironés R, Torregrosa D, Gomez-Codina J et al. 
22
 

 
 
 
 
 
                               67 
 
 
PEBEL_GECP 
16/06_v.2.1_28_Dic_2018 
 
 
 
23
25
26